News
Arrowhead Pharmaceuticals doses first subjects in Phase 1/2 Study of ARO-C3, RNAi therapeutic for treatment of complement mediated diseases ...
These findings suggest complement protein levels may be an important biomarker for type 1 diabetes.
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback